Use of NMDA antagonists for treatment of irritable bowel syndrome (IBS) and compounds with NMDA receptor antagonistic properties

摘要

Described is the use of pharmaceutical compounds having NMDA antagonist activity for treating certain conditions in the gastrointestinal tract, such as functional gastrointestinal disorders, and in particular irritable bowel syndrome (IBS). Also described are pharmaceutical compositions to be used in the treatment of IBS and products comprising such compositions and a pharmaceutical acceptable carrier. Figure 5 shows the results for memantine and Figure 6 shows the corresponding results with 2-amidino-6- (2-amino-2- phenyl)-ethylpyridine. Results and conclusions: Intra-arterially injected memantine reduced, in a dose-dependent fashion, the pelvic nerve activity elicited by distension of the colon (80 mm Hg), as can be seen from Figure 5. The observations hereby provided are consistent with a model in which the non-competitive NMDA-antagonist memantine reduces the pelvic nerve activity elicited by colorectal distension by a peripheral mechanism of action. The data shown in Figure 6 was obtained when the experiment was repeated with 2amidino-6- (2-amino-2-phenyl)-ethylpyridine.